DDInter1156 DDInter1628
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Mercaptopurine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Mercaptopurine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Mercaptopurine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Mercaptopurine {u} (Compound) treats {v} (Disease) Crohn's disease
Crohn's disease {u} (Disease) downregulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Mercaptopurine {u} (Compound) treats {v} (Disease) ulcerative colitis
ulcerative colitis {u} (Disease) downregulates {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Mercaptopurine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) downregulates {v} (Gene) MAST1
MAST1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Mercaptopurine {u} (Compound) binds {v} (Gene) TPMT
TPMT {u} (Gene) regulates {v} (Gene) CEBPZ
CEBPZ {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Mercaptopurine {u} (Compound) treats {v} (Disease) Crohn's disease
Crohn's disease {u} (Disease) upregulates {v} (Gene) IRAK1
IRAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Mercaptopurine {u} (Compound) binds {v} (Gene) PPAT
PPAT {u} (Gene) regulates {v} (Gene) ITGB1BP1
ITGB1BP1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Mercaptopurine {u} (Compound) treats {v} (Disease) Crohn's disease
Crohn's disease {u} (Disease) is associated with {v} (Gene) and {u} (Disease) upregulates {v} (Gene) JAK2
JAK2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Mercaptopurine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Mercaptopurine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Mercaptopurine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Mercaptopurine (Compound) treats Crohn's disease (Disease) and Crohn's disease (Disease) downregulates KLHDC2 (Gene) and KLHDC2 (Gene) is downregulated by Ruxolitinib (Compound)
Mercaptopurine (Compound) treats ulcerative colitis (Disease) and ulcerative colitis (Disease) downregulates FOXJ3 (Gene) and FOXJ3 (Gene) is upregulated by Ruxolitinib (Compound)
Mercaptopurine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) downregulates MAST1 (Gene) and MAST1 (Gene) is bound by Ruxolitinib (Compound)
Mercaptopurine (Compound) binds TPMT (Gene) and TPMT (Gene) regulates CEBPZ (Gene) and CEBPZ (Gene) is upregulated by Ruxolitinib (Compound)
Mercaptopurine (Compound) treats Crohn's disease (Disease) and Crohn's disease (Disease) upregulates IRAK1 (Gene) and IRAK1 (Gene) is bound by Ruxolitinib (Compound)
Mercaptopurine (Compound) binds PPAT (Gene) and PPAT (Gene) regulates ITGB1BP1 (Gene) and ITGB1BP1 (Gene) is downregulated by Ruxolitinib (Compound)
Mercaptopurine (Compound) treats Crohn's disease (Disease) and Crohn's disease (Disease) is associated with JAK2 (Gene) and Crohn's disease (Disease) upregulates JAK2 (Gene) and JAK2 (Gene) is bound by Ruxolitinib (Compound)